Biomind Labs Inc. announced the Company?s completion of the development of a novel thermosensitive nasal gel delivery system for its N, N-dimethyltryptamine and 5-MeO-DMT product candidates. The product candidates are aimed at treating depression, anxiety, addictive disorders, eating disorders, and improving the quality of life of patients suffering from neurodegenerative disorders. The Company?s design of the nasal gel consists of an adequate viscosity liquid, which turns into a mucoadhesive gel almost immediately after insertion into the nasal cavity upon contact with the mucosa at body temperature.